Cooperative Agreement AY1AX000075
Award Date
1/27/25
Completion Date
4/26/28
Dollars Obligated
$7.4M
Federal Agency
National Institutes of Health
Federal Grant Program
93.384
Assistance Type
Cooperative Agreement
Place of Performance
Minnesota, USA
Similar Awards
This $798,512 Project Grant was awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to Luminary Therapeutics, Inc., a small disadvantaged business located in Minnesota. The grant will fund the development of an allogeneic gamma/delta T-cell-based chimeric antigen receptor (CAR) therapy that targets two antigens, mesothelin and chondroitin sulfate proteoglycan-4, expressed in epithelial ovarian carcinoma. The therapy incorporates innovative...
The Project Grant award of $1,525,500.00 was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The award, effective September 1, 2024 through August 31, 2027, supports research efforts by the New York University (NYU) School of Medicine to develop novel technologies for identifying tumor-specific antigens and engineering safer, more effective chimeric antigen receptor (CAR) T cell therapies. The work aims to...
This $1,453,091 Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop an "imaging-enabled, adaptable CAR T cell (IMAC) platform" for the treatment of solid tumors. The key products or services to be delivered under this award include: Refining and optimizing the IMAC method to validate optimal dosing schedules, routes, and concentrations that confer a strong tumor response, and confirming small...
The National Cancer Institute awarded Dartmouth College a $604,627 Project Grant under the Cancer Biology Research (CFDA 93.396) program to study ways to engineer durable antitumor protection using chimeric antigen receptor (CAR) T cell therapies. The project aims to deconvolve CAR T cell heterogeneity to understand how individual T cell subsets behave in vivo and identify engineering strategies to program CAR stem cell-like (TSCM) and tissue-resident memory (TRM) cell fates. This research could...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop and test dual-targeting chimeric antigen receptor (CAR) T-cell therapies for treating T-cell acute lymphoblastic leukemia and T-cell lymphoma. The project aims to create allogeneic (partially-matched donor-derived) CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on the majority of T-cell malignancies. The goal is to...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,088,500.00 to the University of California, Santa Barbara (UCSB) to develop and test a new cellular immunotherapy approach called CAR-M (Chimeric Antigen Receptor Macrophage) for treating prevalent solid tumors and hard-to-treat cancers. The research aims to overcome limitations of existing cellular immunotherapies like CAR-T cells by...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $652,725 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for treating glioblastoma, a deadly brain cancer. The funded project aims to test the safety and feasibility of injecting CAR T-cells engineered to secrete a T-cell engaging antibody (CARV3.TEAM-E...
This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), aims to enhance Chimeric Antigen Receptor (CAR)-T cell therapy for treating solid cancers. The $415,260 award, effective June 1, 2024 through May 31, 2026, will support research at The Methodist Hospital Research Institute in Houston, Texas. The key objectives are to: 1) Investigate the impact of image-guided targeted radionuclide therapy (TRT) on stimulating antitumor immune responses...
This $627,272 federal Project Grant award from the National Cancer Institute (Cancer Treatment Research, CFDA 93.395) supports research led by The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T-cell therapy against pancreatic tumors. The key objectives are to engineer self-propelled, tumor-infiltrating CAR T-cells using synthetic "velocity receptors" that enhance migration speed and tumor penetration. The project will test the motility and...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program is supporting a $1,735,056 research project over 5 years to investigate methods for decoupling the acute toxicities and improving the antitumor efficacy of adoptive cell therapy using chimeric antigen receptor (CAR) T cells. The research team at The Methodist Hospital Research Institute in Houston, Texas aims to determine the role of the anti-inflammatory drug clofazimine in...